New York A02650 ensures patient access to FDA-approved abuse-deterrent opioid medications.

New York A02650 amends the public health law and the insurance law to facilitate patient access to FDA-approved abuse-deterrent opioid medications. The bill mandates that insurance carriers and health plans cover at least one abuse-deterrent opioid analgesic drug product per active ingredient. It prohibits prior authorization requirements or service denials from mandating the use of non-abuse-deterrent opioid products to access abuse-deterrent ones. The bill also limits cost-sharing for abuse-deterrent opioids to the lowest levels applied to non-abuse-deterrent opioids.

New York A02650 ensures patient access to FDA-approved abuse-deterrent opioid medications.

New York A02650 amends the public health law and the insurance law to facilitate patient access to FDA-approved abuse-deterrent opioid medications. The bill mandates that insurance carriers and health plans cover at least one abuse-deterrent opioid analgesic drug product per active ingredient. It prohibits prior authorization requirements or service denials from mandating the use of non-abuse-deterrent opioid products to access abuse-deterrent ones. The bill also limits cost-sharing for abuse-deterrent opioids to the lowest levels applied to non-abuse-deterrent opioids.